Despite two life extension wins, Novartis still finds it tough to convince doctors to use its breast cancer drug Kisqali over Pfizer’s first-to-market Ibrance. Now, …
The FDA had reservations about Merck & Co.’s proposed use of Keytruda around surgery for patients with early triple-negative breast cancer. But less than three …
Novartis’ Kisqali (ribociclib) combination therapy has succeeded in a phase 3 study in premenopausal women with hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) …
Results from a study of 142 women with newly diagnosed metastatic breast cancer will be presented by researchers from Lund University at the world’s biggest …
Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.
